Sanda Win1,2, Robert W M Min3, Jun Zhang4, Gary Kanel1,5, Brad Wanken6, Yibu Chen7, Meng Li7, Ying Wang8, Ayako Suzuki8, Filbert W M Aung9, Susan F Murray10, Mariam Aghajan10, Tin A Than1,2, Neil Kaplowitz1,2. 1. USC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA. 2. Division of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 3. Rush University, Rush Medical College, Chicago, IL. 4. Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China. 5. Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA. 6. CHLA Saban Research Institute, Los Angeles, CA. 7. USC Libraries Bioinformatics Service, Norris Medical Library, Los Angeles, CA. 8. Division of Gastroenterology, Department of Medicine, Duke University, Durham, NC. 9. Brown University, Providence, RI. 10. Ionis Pharmaceuticals, Carlsbad, CA.
Abstract
BACKGROUND AND AIMS: The hepatic mitogen-activated protein kinase (MAPK) cascade leading to c-Jun N-terminal kinase (JNK) activation has been implicated in the pathogenesis of nonalcoholic fatty liver (NAFL)/NASH. In acute hepatotoxicity, we previously identified a pivotal role for mitochondrial SH3BP5 (SAB; SH3 homology associated BTK binding protein) as a target of JNK, which sustains its activation through promotion of reactive oxygen species production. Therefore, we assessed the role of hepatic SAB in experimental NASH and metabolic syndrome. APPROACH AND RESULTS: In mice fed high-fat, high-calorie, high-fructose (HFHC) diet, SAB expression progressively increased through a sustained JNK/activating transcription factor 2 (ATF2) activation loop. Inducible deletion of hepatic SAB markedly decreased sustained JNK activation and improved systemic energy expenditure at 8 weeks followed by decreased body fat at 16 weeks of HFHC diet. After 30 weeks, mice treated with control-antisense oligonucleotide (control-ASO) developed steatohepatitis and fibrosis, which was prevented by Sab-ASO treatment. Phosphorylated JNK (p-JNK) and phosphorylated ATF2 (p-ATF2) were markedly attenuated by Sab-ASO treatment. After 52 weeks of HFHC feeding, control N-acetylgalactosamine antisense oligonucleotide (GalNAc-Ctl-ASO) treated mice fed the HFHC diet exhibited progression of steatohepatitis and fibrosis, but GalNAc-Sab-ASO treatment from weeks 40 to 52 reversed these findings while decreasing hepatic SAB, p-ATF2, and p-JNK to chow-fed levels. CONCLUSIONS: Hepatic SAB expression increases in HFHC diet-fed mice. Deletion or knockdown of SAB inhibited sustained JNK activation and steatohepatitis, fibrosis, and systemic metabolic effects, suggesting that induction of hepatocyte Sab is an important driver of the interplay between the liver and the systemic metabolic consequences of overfeeding. In established NASH, hepatocyte-targeted GalNAc-Sab-ASO treatment reversed steatohepatitis and fibrosis.
BACKGROUND AND AIMS: The hepatic mitogen-activated protein kinase (MAPK) cascade leading to c-Jun N-terminal kinase (JNK) activation has been implicated in the pathogenesis of nonalcoholic fatty liver (NAFL)/NASH. In acute hepatotoxicity, we previously identified a pivotal role for mitochondrial SH3BP5 (SAB; SH3 homology associated BTK binding protein) as a target of JNK, which sustains its activation through promotion of reactive oxygen species production. Therefore, we assessed the role of hepatic SAB in experimental NASH and metabolic syndrome. APPROACH AND RESULTS: In mice fed high-fat, high-calorie, high-fructose (HFHC) diet, SAB expression progressively increased through a sustained JNK/activating transcription factor 2 (ATF2) activation loop. Inducible deletion of hepatic SAB markedly decreased sustained JNK activation and improved systemic energy expenditure at 8 weeks followed by decreased body fat at 16 weeks of HFHC diet. After 30 weeks, mice treated with control-antisense oligonucleotide (control-ASO) developed steatohepatitis and fibrosis, which was prevented by Sab-ASO treatment. Phosphorylated JNK (p-JNK) and phosphorylated ATF2 (p-ATF2) were markedly attenuated by Sab-ASO treatment. After 52 weeks of HFHC feeding, control N-acetylgalactosamine antisense oligonucleotide (GalNAc-Ctl-ASO) treated mice fed the HFHC diet exhibited progression of steatohepatitis and fibrosis, but GalNAc-Sab-ASO treatment from weeks 40 to 52 reversed these findings while decreasing hepatic SAB, p-ATF2, and p-JNK to chow-fed levels. CONCLUSIONS: Hepatic SAB expression increases in HFHC diet-fed mice. Deletion or knockdown of SAB inhibited sustained JNK activation and steatohepatitis, fibrosis, and systemic metabolic effects, suggesting that induction of hepatocyte Sab is an important driver of the interplay between the liver and the systemic metabolic consequences of overfeeding. In established NASH, hepatocyte-targeted GalNAc-Sab-ASO treatment reversed steatohepatitis and fibrosis.
Authors: Rohit Kohli; Michelle Kirby; Stavra A Xanthakos; Samir Softic; Ariel E Feldstein; Vijay Saxena; Peter H Tang; Lili Miles; Michael V Miles; William F Balistreri; Stephen C Woods; Randy J Seeley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Cynthia A Moylan; Herbert Pang; Andrew Dellinger; Ayako Suzuki; Melanie E Garrett; Cynthia D Guy; Susan K Murphy; Allison E Ashley-Koch; Steve S Choi; Gregory A Michelotti; Daniel D Hampton; Yuping Chen; Hans L Tillmann; Michael A Hauser; Manal F Abdelmalek; Anna Mae Diehl Journal: Hepatology Date: 2013-12-13 Impact factor: 17.425
Authors: Jerome Garcia; Rudy Chang; Ross A Steinberg; Aldo Arce; Joshua Yang; Peter Van Der Eb; Tamara Abdullah; Devaraj V Chandrashekar; Sydney M Eck; Pablo Meza; Zhang-Xu Liu; Enrique Cadenas; David H Cribbs; Neil Kaplowitz; Rachita K Sumbria; Derick Han Journal: Front Physiol Date: 2022-09-15 Impact factor: 4.755